Cancers, Free Full-Text
Por um escritor misterioso
Descrição
After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
Cancers, Free Full-Text
Epigenetic regulation during cancer transitions across 11 tumour types
Home - Free ME from Lung Cancer
Vag Diagnose Software Version 311 - Colaboratory
Cancers, Free Full-Text
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization
from Flow Cytometry to Cytomics, Page 2
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
CA: A Cancer Journal for Clinicians - Wiley Online Library
Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer. - Abstract - Europe PMC
Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease - eBioMedicine
de
por adulto (o preço varia de acordo com o tamanho do grupo)
